See more : Shouhang High-Tech Energy Co., Ltd. (002665.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Elutia Inc. (ELUT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Elutia Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- The Brighton Pier Group PLC (PIER.L) Income Statement Analysis – Financial Results
- Agentix Corp. (AGTX) Income Statement Analysis – Financial Results
- Redbubble Limited (RDBBY) Income Statement Analysis – Financial Results
- Tiger Reef, Inc. (TGRR) Income Statement Analysis – Financial Results
- Bestec Power Electronics Co., Ltd. (3308.TW) Income Statement Analysis – Financial Results
Elutia Inc. (ELUT)
About Elutia Inc.
Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 24.75M | 23.85M | 47.39M | 42.68M | 42.90M | 39.04M |
| Cost of Revenue | 13.69M | 12.21M | 28.37M | 22.12M | 23.13M | 23.09M |
| Gross Profit | 11.05M | 11.64M | 19.02M | 20.56M | 19.77M | 15.95M |
| Gross Profit Ratio | 44.67% | 48.80% | 40.14% | 48.17% | 46.08% | 40.84% |
| Research & Development | 4.40M | 7.73M | 9.27M | 4.08M | 2.40M | 2.48M |
| General & Administrative | 14.10M | 16.05M | 13.69M | 10.64M | 0.00 | 0.00 |
| Selling & Marketing | 13.09M | 17.85M | 18.83M | 17.57M | 0.00 | 0.00 |
| SG&A | 27.19M | 33.90M | 32.79M | 30.08M | 25.78M | 21.69M |
| Other Expenses | 9.99M | 4.16M | 3.58M | -2.57M | 0.00 | 0.00 |
| Operating Expenses | 41.58M | 41.63M | 42.05M | 34.16M | 28.18M | 24.17M |
| Cost & Expenses | 55.27M | 53.84M | 70.42M | 56.28M | 51.31M | 47.26M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 5.80M | 5.12M | 5.32M | 5.63M | 5.38M | 5.52M |
| Depreciation & Amortization | 3.51M | 3.57M | 3.73M | 3.86M | 3.90M | 3.80M |
| EBITDA | -31.92M | -27.46M | -15.72M | -12.30M | -2.63M | -2.22M |
| EBITDA Ratio | -128.98% | -110.79% | -40.73% | -22.81% | -10.51% | -11.32% |
| Operating Income | -30.53M | -29.99M | -23.03M | -13.60M | -8.41M | -8.22M |
| Operating Income Ratio | -123.36% | -125.75% | -48.60% | -31.86% | -19.60% | -21.06% |
| Total Other Income/Expenses | -10.70M | -6.16M | -1.75M | -8.20M | -3.50M | -3.32M |
| Income Before Tax | -41.22M | -36.15M | -24.78M | -21.80M | -11.91M | -11.54M |
| Income Before Tax Ratio | -166.58% | -151.57% | -52.28% | -51.07% | -27.76% | -29.56% |
| Income Tax Expense | 28.00K | 34.00K | 55.00K | 26.00K | 30.00K | 26.00K |
| Net Income | -37.66M | -32.90M | -24.83M | -21.83M | -11.94M | -11.57M |
| Net Income Ratio | -152.18% | -137.94% | -52.40% | -51.13% | -27.83% | -29.63% |
| EPS | -2.07 | -2.38 | -2.38 | -2.13 | -1.12 | -1.08 |
| EPS Diluted | -2.07 | -2.38 | -2.38 | -2.13 | -1.12 | -1.08 |
| Weighted Avg Shares Out | 18.16M | 13.83M | 10.44M | 10.23M | 10.67M | 10.67M |
| Weighted Avg Shares Out (Dil) | 18.16M | 13.83M | 10.44M | 10.23M | 10.67M | 10.67M |
Elutia Inc. (ELUT) Q3 2024 Earnings Call Transcript
Elutia to Present at the LD Micro Main Event XVII Conference on Wednesday, October 30
Elutia Announces New Peer Reviewed Publication Highlighting the Robustness of EluPro™, Company's Antibiotic-Eluting BioEnvelope for Implantable Devices
Elutia Celebrates First Year
Elutia Announces First Patient Implant of EluPro™, the World's First Drug-Eluting BioEnvelope for Cardiac Pacemakers and Neurostimulators
Elutia to Participate in Upcoming Investor Conferences
Elutia Inc. (ELUT) Q2 2024 Earnings Call Transcript
Elutia Appoints Ryan Marques, Ph.D., MBA as Vice President of Operations
Elutia to Present at the Emerging Growth Conference on Thursday, July 18
7 Growth Stocks to Buy for Under $5 for Massive Gains
Source: https://incomestatements.info
Category: Stock Reports